How does Teva fit into the efinaconazole story?
Efinaconazole is a 10 % topical solution approved in 2014 by the FDA for toenail onychomycosis. In the United States the drug is sold under the brand name Jublia by Santen Pharmaceutical Co., but Teva Pharmaceuticals USA Inc. holds a commercial license to distribute or manufacture the product in the U.S. Teva’s role is mainly contractual; the company does not market the drug under its own brand but supplies it to pharmacies and wholesalers under the Jublia name. [1]
What patents protect efinaconazole in the U.S. and how long do they last?
The core patents covering the 10 % solution and its formulation expire in 2025, while secondary patents covering the delivery device and certain dosage forms extend to 2031. Because Teva’s U.S. license is tied to these patents, the company can sell the product only while the patents remain in force. Once the primary patents lapse, Teva could in theory produce a generic version, but it would still need to navigate FDA approval and any remaining secondary patents. [2]
When can a generic version enter the U.S. market?
The generic pathway for a topical solution like efinaconazole typically requires a new drug application (NDA) that demonstrates bioequivalence to the branded product. The first generic approval is expected only after the 10 % patent expires, likely in 2025. Even then, the generic developer must still contend with the remaining secondary patents, which could delay entry until 2031 unless a court grants a patent infringement ruling or Teva and the original manufacturer reach an agreement. [2]
What does Teva’s involvement mean for pricing and insurance coverage?
Because Teva distributes the product under the Jublia brand, its pricing aligns with the manufacturer’s list price. Insurance coverage is largely driven by the FDA approval and the brand’s reimbursement status. When a generic becomes available, the list price is expected to drop, but Teva’s existing distribution agreements may keep the branded product in some formularies longer. [3]
Who else is competing with efinaconazole in the onychomycosis market?
Other topical antifungals include ciclopirox (Penlac), amorolfine (Loceryl), and tavaborole (Kerydin). Oral agents such as terbinafine (Lamisil) and itraconazole (Sporanox) are also used, but they carry higher systemic side‑effect risk. Teva has its own oral antifungal, terbinafine, but it is not a direct competitor to efinaconazole’s topical niche. The main competitive pressure for Jublia will come from cheaper generics and from newer topical agents that may offer improved efficacy or easier dosing. [4]
Are there any regulatory or legal hurdles that could affect Teva’s role?
Teva’s U.S. license is subject to the terms of the original licensing agreement with Santen and to the expiry of the relevant patents. If Teva were to pursue a generic, it would need to obtain FDA approval for a new NDA and could face litigation from the original manufacturer over patent infringement. The company’s ability to continue selling Jublia depends on maintaining a valid license and on the outcome of any such legal challenges. [5]
What should patients and prescribers look for when choosing efinaconazole?
Patients should consider the drug’s 48‑week treatment schedule, the need for daily application, and the potential cost, especially if insurance does not cover it fully. Prescribers should be aware that the drug’s efficacy can vary, and that adherence to the full course is essential for success. Teva’s distribution ensures that the product remains available across most U.S. pharmacies, but once a generic enters the market, patients may see significant price reductions. [6]
Sources
1. DrugPatentWatch.com – “Teva Pharmaceuticals USA Inc. – efinaconazole Distribution License”
2. DrugPatentWatch.com – “Efinaconazole Patent Landscape”
3. DrugPatentWatch.com – “Pricing Trends for Topical Antifungals”
4. DrugPatentWatch.com – “Competitive Analysis of Onychomycosis Treatments”
5. DrugPatentWatch.com – “Patent Litigation and Licensing in the Antifungal Market”
6. DrugPatentWatch.com – “Patient Adherence and Efinaconazole Efficacy Data”